Shanghai Pharmaceuticals Holding Co., Ltd (SHA:601607)
18.12
0.00 (0.00%)
Sep 18, 2025, 11:29 AM CST
SHA:601607 Revenue
Shanghai Pharmaceuticals Holding had revenue of 70.83B CNY in the quarter ending June 30, 2025, with 2.27% growth. This brings the company's revenue in the last twelve months to 277.43B, up 3.86% year-over-year. In the year 2024, Shanghai Pharmaceuticals Holding had annual revenue of 275.25B with 5.75% growth.
Revenue (ttm)
277.43B
Revenue Growth
+3.86%
P/S Ratio
0.22
Revenue / Employee
5.54M
Employees
49,402
Market Cap
61.00B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 275.25B | 14.96B | 5.75% |
Dec 31, 2023 | 260.30B | 28.31B | 12.21% |
Dec 31, 2022 | 231.98B | 16.16B | 7.49% |
Dec 31, 2021 | 215.82B | 23.92B | 12.46% |
Dec 31, 2020 | 191.91B | 5.34B | 2.86% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Jiangsu Hengrui Medicine | 30.15B |
WuXi AppTec | 41.90B |
Shenzhen Mindray Bio-Medical Electronics | 32.94B |
Sichuan Biokin Pharmaceutical | 441.19M |
Shanghai United Imaging Healthcare | 10.98B |
Zhangzhou Pientzehuang Pharmaceutical., | 10.52B |
Aier Eye Hospital Group | 21.94B |
Yunnan Baiyao Group Co.,Ltd | 40.84B |
Shanghai Pharmaceuticals Holding News
- 9 months ago - Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million - Benzinga
- 9 months ago - HUTCHMED to divest 45% stake in JV with Shanghai Pharma - Seeking Alpha